·
|
Revenues
totaled $123.7 million (Q4 2008: $129.8 million).
|
·
|
Operating
income increased by 22% to $9.5 million (Q4 2008: $7.7
million).
|
·
|
Net
income from continuing operations attributable to Formula increased by 59%
to $3.7 million (Q4 2008: $2.3
million).
|
·
|
Net
income attributable to Formula reached $8.0 million, an almost three-fold
increase compared to $1.7 million for the fourth quarter of
2008.
|
·
|
Formula’s
consolidated cash and short term investments totaled approximately $158.6
million as at 31 December 2009.
|
·
|
During
the fourth quarter Formula sold its entire stake in nextSource Inc. for a
total consideration of $12.0 million, comprised of cash and release of
bank pledges. Formula recorded a capital gain in the discontinued
operations of $4.3 million.
|
·
|
Revenues
totaled $469.4 million (2008: $503.2 million). The vast majority of
Formula's revenues are generated in NIS (New Israeli Shekel). The decline
is therefore mostly attributed to the negative impact of the NIS vs. US
Dollar devaluation on translation of revenues from NIS to
USD.
|
·
|
Operating
income increased to $35.4 million (2008: $32.5
million).
|
·
|
Net
income from continuing operations attributable to Formula increased by 25%
to $14.2 million (2008: $11.3
million).
|
·
|
Net
income attributable to Formula reached $19.1 million, an increase of 61%
compared to $11.9 million in 2008.
|
·
|
Formula
will distribute a dividend of $1.47 per
share
|
December 31,
2009
(Unaudited)
|
December 31,
2008
(Audited)
|
|||||||
U.S.
$
|
||||||||
(in
thousands)
|
||||||||
CURRENT
ASSETS:
|
||||||||
Cash
and cash equivalents
|
100,205 | 107,847 | ||||||
Short-term
investments
|
58,410 | 46,158 | ||||||
Trade
receivables
|
130,236 | 136,353 | ||||||
Other
accounts receivable
|
22,062 | 15,425 | ||||||
Inventories
|
2,439 | 2,772 | ||||||
Total
assets attributed to discontinued operations
|
27 | 27,614 | ||||||
313,379 | 336,169 | |||||||
LONG-TERM
INVESTMENTS:
|
||||||||
Long
term investments
|
9,922 | 15,844 | ||||||
Investments
in affiliates
|
3,293 | 3,694 | ||||||
13,215 | 19,538 | |||||||
SEVERANCE
PAY FUND
|
44,131 | 38,105 | ||||||
FIXED
ASSETS, NET
|
9,989 | 15,009 | ||||||
OTHER
ASSETS, NET
|
185,725 | 187,801 | ||||||
566,439 | 596,622 | |||||||
CURRENT
LIABILITIES:
|
||||||||
Liabilities
to banks
|
9,845 | 8,481 | ||||||
Trade
payables
|
43,776 | 39,475 | ||||||
Other
accounts payable
|
91,134 | 75,252 | ||||||
Dividend
payable
|
- | 29,964 | ||||||
Liability
in respect of the acquisition of subsidiaries
|
210 | 6,954 | ||||||
Debentures
|
14,639 | 5,157 | ||||||
Total
liabilities attributed to discontinued operation
|
314 | 24,903 | ||||||
159,918 | 190,186 | |||||||
LONG-TERM
LIABILITIES:
|
||||||||
Debentures
|
43,918 | 56,004 | ||||||
Deferred
taxes
|
2,207 | 4,502 | ||||||
Customer
advances
|
1,116 | 1,093 | ||||||
Liabilities
to banks
|
8,556 | 16,640 | ||||||
Liability
in respect of the acquisition of activity
|
1,517 | 1,010 | ||||||
Accrued
severance pay
|
53,893 | 49,817 | ||||||
111,207 | 129,066 | |||||||
EQUITY
|
295,314 | 277,370 | ||||||
566,439 | 596,622 |
Year months ended
December 31,
|
Three months ended
December 31,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
U.S.$
|
U.S.$
|
|||||||||||||||
(in thousands, except per share data)
|
||||||||||||||||
Revenues
|
469,390 | 503,243 | 123,713 | 129,780 | ||||||||||||
Cost
of revenues
|
352,283 | 373,775 | 93,578 | 100,503 | ||||||||||||
Gross
profit
|
117,107 | 129,468 | 30,135 | 29,277 | ||||||||||||
Research
and development costs, net
|
4,430 | 6,564 | 1,469 | 2,080 | ||||||||||||
Selling,
general and administrative expenses
|
77,322 | 90,451 | 19,194 | 19,459 | ||||||||||||
Operating
income
|
35,355 | 32,453 | 9,472 | 7,738 | ||||||||||||
Financial
expenses, net
|
(231 | ) | (5,908 | ) | (1,404 | ) | (722 | ) | ||||||||
35,124 | 26,545 | 8,068 | 7,016 | |||||||||||||
Gain
(loss) on realization of investments
|
- | (337 | ) | - | 67 | |||||||||||
Other
income (expenses), net
|
1,668 | (580 | ) | 1,729 | (249 | ) | ||||||||||
Income
before taxes on income
|
36,792 | 25,628 | 9,797 | 6,834 | ||||||||||||
Taxes
on income
|
8,305 | 3,279 | 2,159 | 1,779 | ||||||||||||
28,487 | 22,349 | 7,638 | 5,055 | |||||||||||||
Share
in gains (losses) of associated companies, net
|
(335 | ) | (216 | ) | (205 | ) | 80 | |||||||||
Net
Income
|
28,152 | 22,133 | 7,433 | 5,135 | ||||||||||||
Attributable
to non-controlling interest
|
13,954 | 10,819 | 3,711 | 2,797 | ||||||||||||
Net
income attributable to Formula's common shareholders from
continuing operation
|
14,198 | 11,314 | 3,722 | 2,338 | ||||||||||||
Net
income from discontinued operation
|
4,878 | 555 | 4,284 | (630 | ) | |||||||||||
Net
income attributable to Formula's common shareholders
|
19,076 | 11,869 | 8,006 | 1,708 | ||||||||||||
Earnings
per share generated from continuing operation :
|
||||||||||||||||
Basic
|
1.03 | 0.84 | 0.35 | 0.18 | ||||||||||||
Diluted
|
1.00 | 0.84 | 0.33 | 0.18 | ||||||||||||
Earnings
per share generated from discontinued operation :
|
||||||||||||||||
Basic
|
0.37 | 0.04 | 0.32 | (0.05 | ) | |||||||||||
Diluted
|
0.36 | 0.04 | 0.32 | (0.05 | ) | |||||||||||
Weighted
average number of shares outstanding:
|
||||||||||||||||
Basic
|
13,200 | 13,200 | 13,200 | 13,200 | ||||||||||||
Diluted
|
13,564 | 13,200 | 13,573 | 13,200 |